City of Hope National Medical Center
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From City of Hope National Medical Center
New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.
Private Company Edition: Immunocore’s $130m round kicked off a series of $100m-plus venture capital deals, including financings for Xilio, Akouos and Pliant. Also, VC investment in cell and gene therapies surged in 2019 and MPM launched two funds with $126 for early cancer research.
Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.
Tech Transfer Roundup: Anixa Thinks Cleveland Clinic IP Offers Potential In Triple-Negative Breast Cancer
Anixa obtains cancer vaccine targeted to proteins common in breast cancer from Cleveland Clinic. Arxx licenses Cancer Research UK antibody that targets tumor microenvironment.
- Academic and Research Institutions
- Other Names / Subsidiaries
- City of Hope Obligated Group